G Goodall

Statistics

Publications

Citations

459

H-Index

Active since

2008

Affiliations

Edwards Lifesciences (Switzerland)(Current)

Health Economics and Outcomes Research (United Kingdom)

Kantonsspital St. Gallen

Eli Lilly (United States)

G Goodall is an author at Edwards Lifesciences (Switzerland) specializing in cost-effectiveness analysis, pharmacoeconomic modeling, and economic evaluation.

ORCID

Publications per year

2008–2019

Publications

The Burden and Impact of Vertigo: Findings from the REVERT Patient Registry

Heike Benecke, Sam Agus, Daniel Kuessner et al. · Frontiers in Neurology · 2013 · 130 citations · Full text

Medicine, Otolaryngology, Occupational Health +13

The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study

G Goodall, Eric Sarpong, Clarice Hayes et al. · BMC Endocrine Disorders · 2009 · 64 citations · Full text

Medicine, Endocrinology, Pharmacology +16

Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients

G Goodall, Mark Lamotte, Mafalda Ramos et al. · Journal of Medical Economics · 2018 · 48 citations · Full text

Medicine, Cardiology, Surgery +17

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost‐effectiveness analysis in the German setting

Thomas Mittendorf, Jayne Smith‐Palmer, L. Timlin et al. · Diabetes Obesity and Metabolism · 2009 · 34 citations

Pharmacy, Endocrinology, Pharmacoeconomics +17

<p>A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients</p>

Jean‐Éric Tarride, Trinh Luong, G Goodall et al. · ClinicoEconomics and Outcomes Research · 2019 · 30 citations · Full text

Medicine, Cardiology, Surgery +17

1–5 of 12